Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

4.80
-0.1150-2.34%
Volume:74.99K
Turnover:361.64K
Market Cap:791.78M
PE:11.36
High:4.86
Open:4.84
Low:4.78
Close:4.91
52wk High:5.08
52wk Low:2.04
Shares:165.13M
Float Shares:96.72M
Volume Ratio:0.54
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4223
EPS(LYR):0.0687
ROE:4.58%
ROA:-1.68%
PB:0.49
PE(LYR):69.77

Loading ...

Interview with Hisense Display Marketing President: Promoting RGB-Mini LED Technology for Mass Market, Chinese Companies Win High-End Display Battle

Deep News
·
Aug 26

TrendForce Forecasts Liquid Cooling Technology Penetration in AI Data Centers to Surge to 33% This Year

Stock News
·
Aug 21

Changsha Public Transport: Beyond Commuting, Connecting Hearts

Deep News
·
Aug 20

Stock Track | Qudian Inc. Soars 5.12% After Q2 Earnings Beat and Strategic Business Decision

Stock Track
·
Aug 13

Chinese online microlender Qudian's Q2 profit jumps on investment gains, revenue slumps on wind down of last-mile delivery

Reuters
·
Aug 13

Qudian Q2 Adj. EPS $0.26 Up From $0.07 YoY, Sales $487.000K Down From $7.338M YoY

Benzinga
·
Aug 13

Qudian Inc. Reports Q2 2025 Results: Revenues Plunge 93.5% to RMB3.5M, Net Income Surges to RMB311.8M, EPS at RMB1.86

Reuters
·
Aug 13

Qudian Inc - Decided to Wind Down Last-Mile Delivery Business

THOMSON REUTERS
·
Aug 13

Qudian Inc. Reports Second Quarter 2025 Unaudited Financial Results

THOMSON REUTERS
·
Aug 13

Qudian Q2 Net Income RMB 311.762 Million

THOMSON REUTERS
·
Aug 13

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire
·
Aug 05

Asian Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading

MT Newswires Live
·
Jul 29

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading, Up 3% for Week

MT Newswires Live
·
Jul 25

Qudian Q1 Adj. EPS $0.12, Sales $3.55M, Company Exits Quarter With Cash & Equivalents Worth $664.607M

Benzinga
·
May 30

Qudian Inc. Reports Q1 2025 Results: Revenue Drops to RMB25.8M, Net Income Swings to RMB150.1M, EPS at RMB0.87

Reuters
·
May 30

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

GlobeNewswire
·
May 24